KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Notes Payables (2016 - 2017)

Historic Notes Payables for Teva Pharmaceutical Industries (TEVA) over the last 7 years, with Q4 2017 value amounting to $1.0 million.

  • Teva Pharmaceutical Industries' Notes Payables fell 9333.33% to $1.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was $1.0 million, marking a year-over-year decrease of 9333.33%. This contributed to the annual value of $1.0 million for FY2017, which is 9333.33% down from last year.
  • Teva Pharmaceutical Industries' Notes Payables amounted to $1.0 million in Q4 2017, which was down 9333.33% from $15.0 million recorded in Q4 2016.
  • In the past 5 years, Teva Pharmaceutical Industries' Notes Payables registered a high of $75.0 million during Q4 2015, and its lowest value of $1.0 million during Q4 2017.
  • In the last 4 years, Teva Pharmaceutical Industries' Notes Payables had a median value of $30.5 million in 2014 and averaged $34.2 million.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Notes Payables surged by 6304.35% in 2015, and later tumbled by 9333.33% in 2017.
  • Teva Pharmaceutical Industries' Notes Payables (Quarter) stood at $46.0 million in 2014, then soared by 63.04% to $75.0 million in 2015, then plummeted by 80.0% to $15.0 million in 2016, then tumbled by 93.33% to $1.0 million in 2017.
  • Its last three reported values are $1.0 million in Q4 2017, $15.0 million for Q4 2016, and $75.0 million during Q4 2015.